An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Albiglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 20 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned End Date changed from 1 Nov 2017 to 1 Feb 2017.
- 02 Feb 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2017.